35.10

0.09% -0.03

After Hours: 35.79 0.69 +1.97%

Atricure Inc (ATRC)

Overview News Price History Option Chain Financials Discussions Forecast

Atricure Inc stock is traded at $35.10, with a volume of 878.24K. It is down -0.09% in the last 24 hours and up +7.11% over the past month. AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Previous Close:

$35.13

Open:

$35.17

24h Volume:

878.24K

Relative Volume:

1.47

Market Cap:

$1.74B

Revenue:

$447.57M

Net Income/Loss:

$-38.92M

P/E Ratio:

-42.29

EPS:

-0.83

Net Cash Flow:

$-1.15M

1W Performance:

+16.34%

1M Performance:

+7.11%

6M Performance:

-11.96%

1Y Performance:

+62.73%

1-Day Range:

$34.18

$35.78

1-Week Range:

$30.41

$38.11

52-Week Range:

$20.20

$43.11

Atricure Inc Stock (ATRC) Company Profile

Name

Atricure Inc

Sector

Healthcare (1161)

Industry

Medical Instruments & Supplies (59)

Phone

513-755-4100

Address

7555 INNOVATION WAY, MASON, OH

Employee

1,300

Twitter

@AtriCure

Next Earnings Date

2024-10-29

Latest SEC Filings

ATRC's Discussions on Twitter

Compare ATRC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATRC Atricure Inc	35.10	1.74B	447.57M	-38.92M	-1.15M	-0.83
ISRG Intuitive Surgical Inc	481.09	179.42B	9.15B	2.61B	1.99B	7.17
BDX Becton Dickinson Co	178.25	52.03B	20.87B	1.50B	2.59B	5.24
ALC Alcon Inc	87.55	44.11B	9.93B	1.12B	1.58B	2.25
RMD Resmed Inc	271.94	40.68B	5.02B	1.31B	1.56B	8.91
WST West Pharmaceutical Services Inc	239.26	17.92B	2.90B	467.20M	306.90M	6.37

Atricure Inc Stock (ATRC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-24	Resumed	JP Morgan	Overweight
Apr-23-24	Upgrade	Oppenheimer	Perform → Outperform
Oct-23-23	Initiated	JMP Securities	Mkt Outperform
Sep-29-23	Initiated	UBS	Buy
Aug-05-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Reiterated	Needham	Buy
Nov-06-20	Reiterated	Needham	Buy
Apr-07-20	Initiated	Oppenheimer	Outperform
Feb-06-20	Initiated	BTIG Research	Buy
Jan-24-20	Reiterated	Needham	Buy
Aug-13-19	Downgrade	Northland Capital	Outperform → Market Perform
Apr-12-19	Initiated	JP Morgan	Overweight
Oct-04-18	Reiterated	Needham	Buy
Aug-02-18	Reiterated	Needham	Buy
Aug-02-18	Reiterated	Stifel	Buy
Jun-18-18	Reiterated	Needham	Buy
Apr-27-18	Reiterated	Needham	Buy
Jan-16-18	Reiterated	Needham	Buy
Nov-02-17	Reiterated	Needham	Buy
Jul-28-17	Reiterated	Needham	Buy
May-30-17	Resumed	Piper Jaffray	Overweight
Jun-30-16	Resumed	JMP Securities	Mkt Outperform
Oct-28-15	Reiterated	Needham	Buy
Oct-06-15	Reiterated	Canaccord Genuity	Buy
Oct-06-15	Reiterated	Needham	Buy

View All

Atricure Inc Stock (ATRC) Latest News

Jul 31, 2025

Is AtriCure Inc. a growth stock or a value stockChart Pattern Updates With High Returns - jammulinksnews.com

Jul 31, 2025

AtriCure 2025 Q2 Earnings Beats Expectations with 22.7% Net Income Improvement - AInvest

Jul 31, 2025

Needham raises AtriCure stock price target to $45 on strong Q2 results By Investing.com - Investing.com South Africa

Jul 30, 2025

AtriCure stock price target raised to $53 from $51 at Canaccord Genuity - Investing.com

Jul 30, 2025

AtriCure stock price target raised to $45 from $44 at Needham - Investing.com Australia

Jul 30, 2025

AtriCure Stock Soars 10.4% on Strong Q2 Revenue Growth - AInvest

Jul 30, 2025

Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Jul 30, 2025

JMP reiterates Market Outperform rating on AtriCure stock after strong Q2 - Investing.com Australia

Jul 30, 2025

The One-year Returns Have Been Favorable for AtriCure (NASDAQ:ATRC) Shareholders Despite Underlying Losses Increasing - 富途牛牛

Jul 30, 2025

AtriCure Q2 2025 slides: Revenue jumps 17%, outlook raised on strong performance - Investing.com Australia

Jul 30, 2025

AtriCure Q2 2025 slides: Revenue jumps 17%, outlook raised on strong performance By Investing.com - Investing.com South Africa

Jul 30, 2025